
|Videos|May 31, 2017
Dr. Hayes Discusses Anti-Estrogen Therapy Beyond 5 Years in Breast Cancer
Author(s)Daniel F. Hayes, MD
Daniel F. Hayes, MD, professor of University of Michigan Comprehensive Cancer Center, discusses anti-estrogen therapy beyond 5 years in breast cancer.
Advertisement
Daniel F. Hayes, MD, professor of University of Michigan Comprehensive Cancer Center, discusses anti-estrogen therapy beyond 5 years in breast cancer.
One of the big questions facing the breast cancer field, Hayes says, is what to do about women who have made it to 5 years on an anti-estrogen therapy.
There are now 4 trials to suggest that continued anti-estrogen therapy beyond 5 years suppresses late recurrence.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5




































